Dafna Capital Management LLC Bei Gene, Ltd. Transaction History

Dafna Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$152.62 - $189.66 $305,240 - $379,320	-2,000 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$152.5 - $216.77 $812,825 - $1.16 Million	-5,330 Reduced 72.71%	2,000 $307,000
Q1 2018 May 15, 2018	SELL	$97.41 - $177.22 $5.26 Million - $9.57 Million	-54,019 Reduced 88.05%	7,330 $1.23 Million
Q4 2017 Feb 14, 2018	SELL	$79.6 - $114.73 $835,799 - $1.2 Million	-10,500 Reduced 14.61%	61,349 $6 Million
Q3 2017 Nov 14, 2017	BUY	$66.19 - $103.46 $4.76 Million - $7.43 Million	71,849	71,849 $7.43 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.